Clinical Trial Detail

NCT ID NCT04269200
Title Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

endometrial carcinoma

Therapies

Durvalumab

Durvalumab + Olaparib

Carboplatin + Durvalumab + Paclitaxel

Carboplatin + Durvalumab + Olaparib + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.